Stem Cell Assay Market Size was valued at USD 4.53 billion in 2023. The stem cell assay market industry is projected to grow from USD 4.83 billion in 2024 to USD 8.54 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.53% during the forecast period (2024 - 2032). The stem cells assays are considered the technique for assessing the effectiveness of antineoplastic medications on the basis of the capacity of adding the development of human tumor cells.
The assay includes the quantitative and the qualitative investigation of high-tech experiments, which can easily affect the tissues and the tumors where the toxicity, added facets, and impurity could be examined. Cellular differentiation is a kind of high technology where the cell changes or adjusts from one cell type to another. Generally, such types of cells have changed for more kinds of specifications. As a part of the stem cell differentiation service, humans have promoted pluripotent stem cells, which possess the capabilities to rise and create a difference in the cell types within the human body parts.
Furthermore, it offers a limitless method of hard-to-source cell types, and hence it can assist in developing great physiological model cells. The rising of advanced medical infrastructures as well as the invention of emerging new technology has always been helpful in the market growth of stem cell assay sectors. According to this, the treatment procedures for several diseases have also changed. Due to the discovery of new treatments and generic medicine facilities, the procedures of treatment methods are completely changed in the medical sector. The cell-based assay isis generally used to show the cell’s viability, cytotoxicity, senescence, and the percentage.
The cell-based assays are generally utilized in high-throughput screening formats. Lots of investors and stem cell assay market stockholders have increased their funds to discover as well as develop the modern technology for safe treatment facilities. Moreover, the high technology always leads to generating advanced cell-based assay treatment, which can easily allow the researchers, laboratory professionals and other medical professionals to utilize the modern technology and find some kinds of the cure and other medicines. The increase in the cell-based assay market has been driven by the factors like the rise in demand for stem cell-based assays in medicine and cure discovery, higher finances for cell-based research and the increase in the several numbers of medicine production industries.
May 21, 2024 - Danaher Corporation, a renowned health sciences technology conglomerate, majorly demonstrated its sustained commitment to the growing stem cell test industry, which specifies yet to believe Danaher is well-positioned to profit on this rapidly expanding market.
A collaboration between GenCure, a BioBridge Global subsidiary, and the University of Texas at San Antonio (UTSA) was outlined by the signing of this master services agreement in December 2023. This articulation spells out their joint efforts in promoting the advancement of cell-based therapies such as products, services and testing.
In October 2023, bit. Bio announced its latest product, ioCRISPR-Ready Cells. These particular cells are for scientists who want to create human gene knockouts that have physiological relevance.
Skin Research Trust (SKAN) and UK’s Wellcome-MRC Cambridge Stem Cell Institute joined hands in September 2023. Among others, they also share a common research endeavor aimed at investigating genomic patterns related to age-related neurodegenerative diseases among the Indian population.
The PromoExQ MSC Growth Medium XF from PromoCell is now available for cell therapy manufacturing applications. The xenoand serum-free medium complies with the company’s EXCiPACT GMP certification scheme and has been optimized for in vitro expansion of human MSCs under a GMP environment, leading to consistent growth and maintenance of numerous types of multipotent MSCs
According to Gamida Cell statement released April 2023, Omisirge (omidubicel-onlv), an allogeneic cell therapy, had been approved by U.S FDA to be used in adult & pediatric patients aged 12 years and above with hematologic malignancies. Approval has been made based on results from a global, randomized Phase III clinical trial, making it the first commercially licensed allogeneic stem cell transplant treatment.
According to Cellular Engineering Technologies (CET), immortalized human stem cells were exclusively authorized for use by John Paul II Medical Research Institute as of March 2023. These stem cells were created via gene editing hESCs using CRISPR/Cas9 technology for manufacturing next-generation native modified PTM cells compared with currently existing cell lines in current bio-production applications. The exclusivity thus creates opportunities for CET to take on the numerous financial and scientific hurdles of iPSC-dependent cell replacement therapy.
BrainStorm Cell Therapeutics announced in January 2023 that it would be donating biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium biorepository for research purposes. These specimens consist of serum as well as cerebrospinal fluid (CSF) collections obtained from clinical trial subjects administered with a placebo.In April 2023, the US FDA approved Omisirge (omidubicel-onlv), a substantially modified allogenic (donor) cord blood-based cell therapy.
COVID-19 Analysis:
The global pandemic has raised at the end of the year 2019. After that, everything has just changed. Due to the global epidemic, most of the country’s governments have been stepping up strict lockdown procedures. According to this, the commercial activities in the national or international fields have closed for a period of time. Most companies face a huge loss due to insufficient raw materials as well as the lack of labor for which all the manufacturing work has been stopped. The stoppage of international cargo vehicles has placed a direct impact on the global stock market. According to this, the stem cell assay market share first time faced a huge loss in the trading business sectors.
To increase the production work, most of the investors have increased their investment, but the lack of emergency equipment and insufficient raw materials show those investors a huge loss inside the investment and business sectors. At the same time, those new faces who wanted to collaborate and willing to sign an agreement of business deals didn’t make it due to the closure of the international market of stem cell assay. According to this, every company has been facing a huge challenge during lockdown time.
The international stem cell assay market growth sectors have always depended on the global population growth and increasing health awareness. During the pandemic, the global market sectors have been crashed, but some of the industry's key market drivers have continuously performed their products. Somehow it might be difficult to manage the demand of the global needs, but it can be a little bit helpful for the patients.
According to the growth of the world population, the increase of new diseases has also significantly raised. But in terms of high-tech and advanced medical equipment making, some companies have waited on the opening of market sectors. To overcome the pandemic situation and release the maximum number of production has always been a major fact for every company.
In the present market of stem cell assay, lots of investors and new business makers have introduced for which the competition level between such sectors is so high. Due to the demand of several people, the world needs better and high-quality medicines as well the cure products which have the capabilities to give a perfect treatment for the patients. This factor creates a lot of market opportunities for the new faces who want to place their business within the market.
During the pandemic, companies around the world faced not only a huge loss but also the market have seen an increase in products, manufacturing equipment and even raw materials. Due to the high cost of the raw materials, not every industrial sector is able to make the production work.
Cumulative Evaluation of the Market:
Most of the industrial and production work has stopped due to the closer of international commercial activities. The market demand for the stem cell assay has been increased so far, but there are no companies in the world that have the capabilities to meet the current market demands. The challenges for every company, as well as the industrial sectors, have been raised significantly. Nobody knows when this pandemic is going to be an end. During the strict lockdown, the international cargo tonnage could not make the clearance to enter the region for which there has been a shortage of raw materials in the industrial sectors. Due to the shortage of raw materials and other useful industrial equipment, the investors have faced a huge loss on the stoppage of production work. Most of the investors have bound to set a permanent shutdown for their companies.
During the global pandemic, not only the investors but also the stem cell assay market stockholder also faced a tremendous challenge to overcome the situation. Every medical sector needs advanced and modern medical facilities to treat the disease. But the lack of insufficient raw materials has led the global market down during the lockdown period of time.
According to the market analysis report of stem cell assay, the entire market has been segmented into six parts product, technology, application, assay, end-user and regional sectors.
On the basis of product type, the stem cell assay market has been segmented into six sections microelectrode arrays, flow cytometers, cell imaging systems, automated cell counters, kits and others. The kit section is further subdivided into four parts mesenchyme stem cell kits, induced pluripotent stem cell kits, umbilical cord stem cells and others.
On the basis of the technology section, the market of stem cell assay has been classified into three types micro fabricated assisted technology, microfluidics-based cell trap technologies and others.
With the assay section, the market has been divided into five parts cell viability & toxicity assays, cell identification assays, cell proliferation assays, cell apoptosis assays and others.
With the application basis, it is further classified into five parts orthopedic & musculoskeletal spine, dermatology, cardiovascular, central nervous system and others.
In the end-user parts, the market has been segmented into biotechnology industries, research organizations, academic institutes and others.
North America is the only region that holds the maximum number of market stocks in the stem cell assay market sectors. According to the raise in emerging technology, the global market always demands the most high-tech medical accessories as well as medicines that can easily control the disease. But in developing countries, the market has been significantly improved due to the serious effort of the government. The increase in health awareness also raises to boost the present market growth. During the pandemic, the economic sectors in several business platforms have been slowed down, but in the developing countries, the marketer and key stockholders are always focusing on the eye to improve the production rate to meet the challenges of the global demands. In the Asia-Pacific regions, India, China, Japan, Russia have also led significant market growth in the current stages.
Key Companies in the Breast Biopsy Market include
Just after the release of the lockdown, the global market has been opened significantly, which helped to give a chance for the market’s most prominent players to increase their production rate. Due to the challenges that have been raised in the recent market, new business players have been introduced in the field for which the competition within the market has been increased so heavily. Some of the lists of global key market players are:
Recent Market Development:
The drug discovery part is one of the essential parts to increase the growth of the high market demand of the stem cell assay in the present world. The highly established huge number of medical infrastructures as well as the modern manufacturing plants have definitely improved the stem cell assay market sectors.
Report Overview:
The stem cell assay market report includes detailed information on the different factors of market share, revenue and CAGR report. The analysis report also mentioned how the global market sectors were hugely affected during the global epidemic era. The investors and market’s most prominent players lists are also included in this report. This report also helps to understand the market segmentation process of different sections.
| Report Attribute/Metric | Details |
| Â Â Market Size | USD 8.54 Billion |
| Â Â CAGR | Â 8.53 % (2024-2032) |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2022 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | By Product Type, Assay, Application, End User |
| Â Â Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Cell Biolabs, Inc., Thermo Fisher Scientific, Hemogenix, Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellular Dynamics International Inc., STEMCELL Technologies Inc |
| Â Â Key Market Opportunities | Increasing demand for regenerative therapies to treat chronic diseases |
| Â Â Key Market Drivers | The growing focus on regenerative medicine, which relies heavily on stem cell research |
Stem Cell Assay Market Highlights:
Frequently Asked Questions (FAQ) :
Stem Cell Assays are a technique for analyzing living cells on the parameters of shape, size, and others with the aim of measuring the biochemical and cellular functioning of the cells. This makes stem cell assays to be extensively utilized in industrial practices of drug development.
Stem Cell Assays Market is expected to exhibit a strong 8.53% CAGR over the forecast period from 2024 to 2032.
The growing biotechnology industry is the major driver for the Stem Cell Assays Market.
The Americas hold the largest share in the Stem Cell Assays Market.
Leading players in the Stem Cell Assays Market include GE Healthcare, Promega, and Thermo Fisher, among others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
